ArticleTranslational lung cancer research2026

Neoadjuvant or conversion anti-PD-1/PD-L1 immunotherapy combined with chemotherapy improves 2-year survival and achieves high pathological complete response rate in patients with stage IIB-IIIB small-cell lung cancer.

Zhiyuan Gao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.